About US
Contact us
-
Chinese company Fosun acquires majority stake in Gland Pharma for $1.26bnChinese international conglomerate and investment company Fosun Group will acquire a majority stake of approximately 86% within Indian pharmaceutical company Gland Pharma for a value of up to $1.26bn.2016/7/28
-
Mylan and Biocon receive MAA review acceptance from EMA for PegfilgrastimUK-based pharmaceutical company Mylan and Indian biopharmaceutical company Biocon have received the European Medicines Agency (EMA) acceptance for review of Mylan's Marketing Authorisation Application2016/7/27
-
EMA CHMP receives positive opinion for Eisai’s combination treatment for RCCJapanese-based Eisai has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on lenvatinib mesylate in combination with everoli2016/7/27
-
Suicide link has FDA staffers iffy on Valeant's brodalumabValeant ($VRX) has been touting the potential of psoriasis candidate brodalumab to help the struggling company stage its turnaround. But ahead of an advisory committee meeting to assess the drug, FDA2016/7/26
-
Pfizer, Gilead and others ignore complaints, raise prices in Q1: WSJTuring Pharmaceuticals and Valeant ($VRX) may have touched off a public and congressional firestorm over drug pricing last fall, butdrugmakershaven't given up thetactic. Despite all of the conversatio2016/7/26
-
The Art and Science of Forecasting with Clinical InformaticsThe art and science of forecasting with clinical informatics The pharmaceutical industry continues to strive to improve the quality and efficiency of clinical trials but many challenges remain with2016/7/25
-
Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen salesIn the second straight resounding vote in favor of a biosimilar in as many days, Sandoz’s version of Amgen’s Enbrel earned unanimous support from an FDA panel Wednesday. With the 20-0 vote, Novartis’2016/7/25
-
Pfizer's superselling Prevnar 13 jab wins expanded use in U.S.Already the world’s best-selling vaccine, Pfizer’s ($PFE) Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49. Prevnar, which reeled in $6.2 billion last ye2016/7/22
-
In unanimous vote, FDA committee backs Amgen's Humira biosimWith billions at stake, Amgen’s biosimilar of AbbVie megablockbuster Humira won the unanimous backing of an FDA panel Tuesday, putting the company just an FDA approval away from a potentially huge sal2016/7/22
-
The Art and Science of Forecasting with Clinical InformaticsThe art and science of forecasting with clinical informatics The pharmaceutical industry continues to strive to improve the quality and efficiency of clinical trials but many challenges remain with2016/7/21